0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-1041.55%PremiumJan 17, 2025Expiry Date6.84Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Adaptimmune Therapeutics Stock Discussion
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
so the spike in cash is from financing, fyi
after the product is approved, profitable, it's your time to shine.
$Adaptimmune Therapeutics (ADAP.US)$
come on
No comment yet